Written by: Carrie Ghose Staff reporter Columbus Business First
The Big Ten has a new technology licensing champion. Diehard Ohio State University fans aren’t gonna like it.
The University of Michigan reported $78.8 million in fiscal 2015 royalties and other income from licensing technology from its researchers, more than quadrupling the prior year’s income. It sold up-front royalties on a drug for a genetic disease for $65.6 million in November 2014, a few months after the drug won regulatory approval.
Ohio State had a 12 percent jump in income to $2.5 million, remaining No. 11 in the 14-school Big Ten Conference for technology commercialization income for the year ended June 30, 2015, according to my compilation of results from the annual survey by the Association of University Technology Managers.
OSU has been making steady incremental progress in a six-year effort to get more of its research out of labs and into market through manufacturing licenses and spinout companies. But after again reorganizing its commercialization efforts in 2015, the university is measuring impact in other ways. As of this year it has 48 active spinoff companies – four times as many as in 2010– that are gaining sales and creating jobs.
See the embedded spreadsheet for the tech commercialization champs of the Big Ten, ranked by fiscal 2015 adjusted gross licensing income, with year-over-year change, 2015 spending on research, and incomes for both 2014 and 2013. The 2015 rankings are below as well.
Nationwide, the Technology Managers survey found:
- Universities, hospitals and research institutions disclosed 25,313 new inventions, 5 percent more than in 2014.
- They filed 15,953 U.S. patent applications, a 15 percent increase, and patents issued grew by 5 percent to 6,680.
- They formed 1,012 startups, up 11 percent, and 72 percent of those stayed in the institution’s home state.
Northwestern University has been the perennial top in the survey among Big Ten schools, thanks to its blockbuster drug Lyrica, a treatment for fibromyalgia, epilepsy and seizures. Sold by Pfizer Inc., Lyrica is an example of how patience pays off: It took 15 years to develop before its 2005 market launch. Royalties and lump-sum sales of royalty rights brought the school more than $1 billion over the next nine years before running out.
Northwestern still has plenty of ammo, with $62.3 million in 2015 income making in No. 2. And another blockbuster is to come: This year a spinout making a new type of antidepressant was acquired.
Michigan’s big payout came from Cerdelga, an oral therapy for adult patients with Gaucher disease – in which a missing key enzyme leads to fatty buildups that cause anemia and other symptoms. It sold 75 percent of the royalty stream in 2014 to PDL BioPharma, so after the one-time deal its fiscal 2016 income may go down.
Michigan State University also saw its income more than double in 2015. I sent a message asking why.
Fiscal 2015 licensing income
- University of Michigan: $78,779,947
- Northwestern University: $62,278,647
- University of Wisconsin-Madison: $39,970,000
- University of Illinois: $31,578,587
- University of Minnesota: $18,526,963
- Rutgers: $15,381,315
- Michigan State University: $8,579,211
- Indiana University: $6,847,143
- University of Nebraska: $6,511,937
- Purdue University: $6,377,899
- Ohio State University: $2,459,946
- University System of Maryland: $2,243,403
- Penn State University: $1,957,775
- University of Iowa: $1,499,681
Originally published on Dec 9, 2016, 1:36pm EST
Read original article here.